KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Pacira BioSciences (PCRX) over the last 16 years, with Q3 2025 value amounting to $545.1 million.

  • Pacira BioSciences' Total Non-Current Liabilities fell 2761.03% to $545.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $545.1 million, marking a year-over-year decrease of 2761.03%. This contributed to the annual value of $754.9 million for FY2024, which is 1109.09% up from last year.
  • According to the latest figures from Q3 2025, Pacira BioSciences' Total Non-Current Liabilities is $545.1 million, which was down 2761.03% from $754.3 million recorded in Q2 2025.
  • Pacira BioSciences' Total Non-Current Liabilities' 5-year high stood at $1.3 billion during Q4 2021, with a 5-year trough of $545.1 million in Q3 2025.
  • Its 5-year average for Total Non-Current Liabilities is $779.7 million, with a median of $745.1 million in 2024.
  • Per our database at Business Quant, Pacira BioSciences' Total Non-Current Liabilities soared by 10076.68% in 2021 and then plummeted by 3640.89% in 2023.
  • Over the past 5 years, Pacira BioSciences' Total Non-Current Liabilities (Quarter) stood at $1.3 billion in 2021, then plummeted by 31.79% to $878.1 million in 2022, then decreased by 22.61% to $679.6 million in 2023, then grew by 11.09% to $754.9 million in 2024, then decreased by 27.8% to $545.1 million in 2025.
  • Its Total Non-Current Liabilities was $545.1 million in Q3 2025, compared to $754.3 million in Q2 2025 and $764.3 million in Q1 2025.